Myriad Genetics (MYGN) News Today $14.51 -0.83 (-5.41%) (As of 12/11/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period UBS Initiates Coverage of Myriad Genetics (MYGN) with Neutral RecommendationDecember 11 at 8:51 AM | msn.comLeerink Partnrs Expects Lower Earnings for Myriad GeneticsMyriad Genetics, Inc. (NASDAQ:MYGN - Free Report) - Research analysts at Leerink Partnrs reduced their Q1 2025 EPS estimates for shares of Myriad Genetics in a research note issued to investors on Monday, December 9th. Leerink Partnrs analyst P. Souda now anticipates that the company will post eaDecember 11 at 7:20 AM | marketbeat.comMyriad Genetics Inc (MYGN) Expands Board with Appointment of Mark S. DavisDecember 10 at 7:47 PM | gurufocus.comMyriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic TestingDecember 10 at 6:26 PM | globenewswire.comMyriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board MemberDecember 10 at 4:05 PM | globenewswire.comMyriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer GuidelinesDecember 10 at 10:37 AM | markets.businessinsider.comMyriad Genetics (NASDAQ:MYGN) Stock Rating Lowered by Leerink PartnrsLeerink Partnrs downgraded shares of Myriad Genetics from a "strong-buy" rating to a "hold" rating in a research note on Monday.December 10 at 7:37 AM | marketbeat.comMyriad Genetics (NASDAQ:MYGN) Coverage Initiated by Analysts at UBS GroupUBS Group started coverage on shares of Myriad Genetics in a research note on Tuesday. They issued a "neutral" rating and a $18.00 price target on the stock.December 10 at 7:16 AM | marketbeat.comDisciplined Growth Investors Inc. MN Purchases 440,107 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)Disciplined Growth Investors Inc. MN raised its position in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 21.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,527,435 shares of theDecember 10 at 6:54 AM | marketbeat.comLeerink Partners Downgrades Myriad Genetics (MYGN)December 10 at 5:36 AM | msn.comMyriad announces its Prolaris test is still classified as ‘Advanced Tool’December 10 at 12:36 AM | markets.businessinsider.comNCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic AssessmentDecember 9 at 7:36 PM | markets.businessinsider.comMyriad Genetics to Present New Breast Cancer Risk Assessment Data at 2024 San Antonio Breast Cancer SymposiumDecember 9 at 4:38 PM | quiverquant.comMyriad Genetics to Present New Data at San Antonio Breast Cancer SymposiumDecember 9 at 4:05 PM | globenewswire.comMyriad Genetics (NASDAQ:MYGN) Cut to "Market Perform" at Leerink PartnersLeerink Partners lowered shares of Myriad Genetics from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $30.00 to $21.00 in a research report on Monday.December 9 at 8:09 AM | marketbeat.comLeerink downgrades Myriad Genetics on reimbursement, competitive headwindsDecember 9 at 6:48 AM | tipranks.comWellington Management Group LLP Sells 1,545,842 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)Wellington Management Group LLP lowered its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 18.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,716,583 shares of the compDecember 9 at 5:07 AM | marketbeat.comMyriad Genetics (NASDAQ:MYGN) Hits New 52-Week Low - Here's What HappenedMyriad Genetics (NASDAQ:MYGN) Reaches New 12-Month Low - What's Next?December 6, 2024 | marketbeat.comPoint72 Asset Management L.P. Boosts Stake in Myriad Genetics, Inc. (NASDAQ:MYGN)Point72 Asset Management L.P. raised its holdings in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 26.7% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,063,711 shares of the companyDecember 6, 2024 | marketbeat.comMyriad Genetics, Inc. (NASDAQ:MYGN) Position Boosted by Verition Fund Management LLCVerition Fund Management LLC increased its holdings in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 946.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 88,903 shares of the company's stockDecember 6, 2024 | marketbeat.comMyriad Genetics, Inc. (NASDAQ:MYGN) Shares Acquired by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. lifted its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 4.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,083,302 shares oDecember 5, 2024 | marketbeat.comEdgestream Partners L.P. Invests $1.53 Million in Myriad Genetics, Inc. (NASDAQ:MYGN)Edgestream Partners L.P. acquired a new position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 55,842 shares of the company's stock, valued at approximatDecember 4, 2024 | marketbeat.comFisher Asset Management LLC Boosts Position in Myriad Genetics, Inc. (NASDAQ:MYGN)Fisher Asset Management LLC boosted its stake in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 47.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 602,842 shares of the company's stock after buying an adNovember 28, 2024 | marketbeat.comMyriad Genetics Settles Shareholder Lawsuits with ReformsNovember 27, 2024 | markets.businessinsider.comMyriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Recommendation of "Hold" by AnalystsShares of Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) have earned a consensus rating of "Hold" from the twelve ratings firms that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, three have given a hold recommendation and seven hNovember 27, 2024 | marketbeat.comMyriad Genetics, Inc. (NASDAQ:MYGN) Shares Bought by Loomis Sayles & Co. L PLoomis Sayles & Co. L P lifted its holdings in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 153.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,189,601 shares of the company's stock after purchasing an adNovember 25, 2024 | marketbeat.comMyriad Genetics, Inc. (NASDAQ:MYGN) Stock Holdings Increased by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 426.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 115,036 shares of theNovember 25, 2024 | marketbeat.comNatixis Advisors LLC Acquires 44,646 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)Natixis Advisors LLC lifted its holdings in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 16.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 320,013 shares of the company's stock after purchasing an additional 44,646 sharesNovember 22, 2024 | marketbeat.comMyriad Genetics Expands Partnership with Illumina to Enhance Genomic Profiling for Cancer DetectionNovember 20, 2024 | quiverquant.comMyriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2November 20, 2024 | globenewswire.comMyriad Genetics (NASDAQ:MYGN) Lowered to Hold Rating by StockNews.comStockNews.com cut shares of Myriad Genetics from a "buy" rating to a "hold" rating in a research report on Wednesday.November 20, 2024 | marketbeat.comMyriad announces Prequel Prenatal Screening can be performed at 8 weeksNovember 19, 2024 | markets.businessinsider.comMyriad Genetics (NASDAQ:MYGN) Reaches New 1-Year Low After Analyst DowngradeMyriad Genetics (NASDAQ:MYGN) Sets New 52-Week Low on Analyst DowngradeNovember 19, 2024 | marketbeat.comMyriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into PregnancyNovember 19, 2024 | markets.businessinsider.comMyriad Genetics price target lowered to $21 from $32 at Morgan StanleyNovember 19, 2024 | markets.businessinsider.comMorgan Stanley Has Lowered Expectations for Myriad Genetics (NASDAQ:MYGN) Stock PriceMorgan Stanley reduced their price objective on Myriad Genetics from $32.00 to $21.00 and set an "equal weight" rating on the stock in a report on Monday.November 18, 2024 | marketbeat.com71,739 Shares in Myriad Genetics, Inc. (NASDAQ:MYGN) Bought by State of New Jersey Common Pension Fund DState of New Jersey Common Pension Fund D purchased a new position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 71,739 shares of the company's stock, valued at approximately $1,96November 18, 2024 | marketbeat.comMYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the FirmNovember 17, 2024 | globenewswire.com173,626 Shares in Myriad Genetics, Inc. (NASDAQ:MYGN) Purchased by Simplify Asset Management Inc.Simplify Asset Management Inc. purchased a new position in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 173,626 shares of the company's stock, valued at approximately $4,756,0November 15, 2024 | marketbeat.comMYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the FirmNovember 14, 2024 | businesswire.comMyriad Genetics price target lowered to $24 from $34 at ScotiabankNovember 14, 2024 | markets.businessinsider.comMyriad Genetics (MYGN) Gets a Buy from ScotiabankNovember 14, 2024 | markets.businessinsider.comMYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the FirmNovember 13, 2024 | prnewswire.comMyriad Genetics price target lowered to $24 from $30 at Piper SandlerNovember 12, 2024 | markets.businessinsider.comMYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the FirmNovember 11, 2024 | globenewswire.comMyriad Genetics: Overcoming Setbacks with Strategic Resilience and Growth ProspectsNovember 11, 2024 | markets.businessinsider.comMyriad Genetics (NASDAQ:MYGN) Price Target Cut to $24.00 by Analysts at Piper SandlerPiper Sandler decreased their price objective on Myriad Genetics from $30.00 to $24.00 and set a "neutral" rating on the stock in a report on Monday.November 11, 2024 | marketbeat.comMyriad Genetics, Inc. (MYGN) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | seekingalpha.comMyriad Genetics Reports Solid Q3 2024 Growth Amid ChallengesNovember 9, 2024 | markets.businessinsider.comMyriad Genetics reports Q3 adjusted EPS 6c, consensus 2cNovember 8, 2024 | markets.businessinsider.com Get Myriad Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter. Email Address The indicator behind Nvidia’s rally has a new prospect (Ad)Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run… All you have to do is follow this link here MYGN Media Mentions By Week MYGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MYGN News Sentiment▼0.260.95▲Average Medical News Sentiment MYGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MYGN Articles This Week▼265▲MYGN Articles Average Week Get Myriad Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ALKS News FOLD News GERN News LGND News MNKD News CLDX News DVAX News BCRX News NVAX News INVA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MYGN) was last updated on 12/11/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredWaveBot: The Automated Trading Tool for This Bull MarketThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myriad Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Myriad Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
